Portfolio


NINA

NINA MEDICAL Ltd.

NINA Medical develops the world’s first non invasive treatment for the enlarged prostate – BPH.


The Need : Existing solutions do not meet the BPH market needs

Enlargement of the prostate (Benign Prostatic Hyperplasia – BPH) is part of the normal aging process in men; more than 50% of men over the age 50, and more than 70% of men over 60 suffer from symptoms associated with BPH. These include: difficulties to start urinating, weak urine flow, incomplete voiding of the bladder, multiple wake ups at night – nocturia and disturbed sleep. Although BPH is primarily classified as a quality-of-life issue, it is also a risk factor for complications including recurrent infections, bladder damage and chronic kidney failure.
Current treatment options include medications (alpha blocker, 5-alpha reductase inhibitor), minimally invasive surgical treatments (UroLift, REZUM, iTind) and full surgery (TURP, HoLEP, PVP).
Medications have side effects, including sexual disfunction, and their efficacy degrades with time.
Minimally invasive treatment options are considered emerging technologies, but they are all transurethral – they require the insertion of surgical tools into the penis.

As a result, most men choose to avoid or postpone conventional medical care. Many of them are experiencing a significant degradation in quality-of-life. For them, a non invasive treatment option would be the treatment of choice.
In the USA, more than 30 million men suffer from BPH, most of them (about 18 million) do not consume any conventional treatment.
Minimally invasive solutions are selected by less than 1% of the market, annually.


The Solution: The first non invasive treatment for BPH

In contrast to the transurethral or transrectal approach of the common practice, NINA Medical approaches the prostate from the perineum, in a completely non invasive manner.
The company is developing the LOTUS-1 diagnostic-therapeutic system, for the urologist's office. Designed as a treatment chair for a patient in a natural sitting position, the LOTUS-1 employs focused ultrasound for therapy by selective thermal ablation of prostate tissue, combined with diagnostic ultrasound for imaging, both approach the prostate from the perineum, non invasively. A new ultrasound imaging script was invented by the company, exposing the profile of the therapeutic beam inside the body; this provides real-time feedback about the actual location of the focal point within the body before and during the ablation process, for better safety and efficacy.
NINA Medical defines a new category in the market – the non invasive treatment, addressing a market share of more than 60% of men who suffer from the enlarged prostate.


The Team

Shmuel Ben-Ezra, co-founder and CEO
Yoni Hertzberg, co-founder and CTO
Zohar Gendler, Chairman of the board
Prof. Gilad Amiel, Medical director
Prof. Mark Emberton, Advisor

Contact Information

Shmuel Ben Ezra –Founder and CEO

P.O. Box 1252, Nazareth Illit 17111, Israel
E-mail: Shmuel@ninamed.com
Cell: +972-54-2445818
Work: +972-4-6098600 
Fax: +972-4-6098611 


Investors - Contact Us

Entrepreneurs - Contact Us